CORDIS oferuje możliwość skorzystania z odnośników do publicznie dostępnych publikacji i rezultatów projektów realizowanych w ramach programów ramowych HORYZONT.
Odnośniki do rezultatów i publikacji związanych z poszczególnymi projektami 7PR, a także odnośniki do niektórych konkretnych kategorii wyników, takich jak zbiory danych i oprogramowanie, są dynamicznie pobierane z systemu OpenAIRE .
Rezultaty
Deliverable 1. Data management Plan. Deliverable 2. Progress and financial periodic and final reports as stipulated in the Grant Agreement.We will ensure the protection of all resulting Intellectual Property as much as possible. The proposed project will adopt Open Science practices to improve the impact of the research findings by ensuring access to all, which complies with the Open Access (OA) mandate of the Model Grant Agreement. There will be OA to research outputs, including OA publication in OA journals (e.g., eLife), deposition of data in public data repositories (e.g., GEO or SRA), and depositing an OA version of publications in the institutional repository (researchrepository.ucd.ie). Data will also be shared early on preprint servers (BioRXiv) and made available in OpenAIRE, an open infrastructure for sharing and research dissemination. Patient data will be managed carefully. The clinicians will provide pseudonymised information to prevent identification. Moreover, a copy of the published work, as well as yearly updates, will be sent to the participating patients by the clinicians. Outcomes from the study will be presented to both scientific audiences at conferences and at public eventsData will be managed in line with the FAIR principles according to the Science Europe Guidelines. Data description: Patient data is supplied to researchers in pseudonymised form. This project will generate RNA-sequencing and epitranscriptomic sequencing datasets, which do not possess patient identifying information. OMICs datasets will be deposited on OA repositories following publication. Documentation of the data: Each individual’s samples are assigned a permanent unique identifier to ensure traceability and no duplication of work, improve reproducibility, and accurate analysis of patient groups. This also allows easy identification of a sample should an individual decide to withdraw from the study and data should be destroyed. Storage and backup: Data generated will be stored on the UCD assigned cloud server as well as on physical hard drives which will be labelled and kept in locked filing cabinets in the office of Dr. Brennan. Researchers working on the project will be provided access to a designated project folder so that all data compiled across sites will be stored together and accessible. No patient information however is ever uploaded to the cloud server. Ethical and legal compliance: The current studies and codes of conduct have been approved by the Beaumont hospital ethics committee. Patient info is pseudonymised on-site by the designated member of the clinical team and patient identifying information is never shared with the researchers. Data sharing and long-term preservation: Clinical data and biological data are assigned a unique identifier which will be used in all subsequent publications, etc. Data generated will be deposited in OA repositories indefinitely. Biological data stored by FutureNeuro can be kept up to 15 years as per ethical approval or until an individual request to be withdrawn in which case it is destroyed. Data management responsibilities and resources: Prof Henshall is the data steward for FutureNeuro. Local data steward at UCD is Paul Sketon and Jenny O’Neill.
Deliverable: Report on dissemination, exploitation, public engagement, and publications.Dissemination: The outcomes of MethylMiR will be disseminated to maximise our outreach to those communities that will be primary beneficiaries of the proposed work, including research-performing Higher Education Institutions, clinicians, and industry Research and Development. (i) Scientific articles will be published in high-impact and OA peer-reviewed journals (e.g., Plos Biology, eLife) and will be also deposited in the OA institutional repository, which complies with the OA mandate of the Model Grant Agreement (section 1.2.4). They will be accompanied by a press release in several outlets; UCD media, FutureNeuro communications, national print, and online media. It is expected that MethylMiR will generate at least 2 high-impact publications (e.g., m6A-miRNA function in the brain, and METLL3 inhibitor as a novel therapeutic). (ii) Further dissemination will take place at national and international conferences (e.g., European Society of Neuroscience (FENS), The Epitranscriptome EMBL conference) through both poster and oral presentations. This will raise our profile within the science community to inform on the progress of MethylMiR and promote network formation. (iii) Seminars will be held at UCD and FutureNeuro and during secondments at host institutions. Communication: In order to contribute to a scientifically literate public we will regularly interact and communicate with the public. Examples include (i) A lecture at the Epilepsy Ireland annual conference which is designed for patients and carers. (ii) UCD Research days, including the Conway Institute’s Annual Festival of Science. (iii) UCD Summer Schools, working in partnership with school students who aspire to go to university and to promote our research and science as a career. (iv) Participation in communications training at UCD, to spread research results via radio, print media, internet, and social media (@UCD_Research, >11.8k followers and @Futureneuro_ie, >2.2k followers). (v) I will participate in public outreach activities such as Dublin Pint of Science to disseminate my research to the wider general public. (vi) Participation in international women in science events. Exploitation: Several potential exploitable results have been identified from the current proposal in consultation with Dr Ena Walsh Case manager and life sciences knowledge transfer specialist at UCD NOVA. These include identifying brain signatures of m6A, which may distinguish epilepsy from non-epileptic human brain. There may also be information gleaned from this data related to drug responses etc. Future studies will be designed to determine whether these signatures can be detected in the blood of patients, which may be exploited as potential biomarkers of the disease. These unique molecular signatures (brain and blood) will be presented to relevant supports at UCD and FutureNeuro to ensure the intellectual protection of these findings. The anti-epileptogenesis study using the ST compound could lead to breakthroughs in the treatment of disease. The host lab and FutureNeuro place a strong emphasis on the exploitation of data and have strong links to industry (ST, Roche, and Janssen). The goals of this project are well aligned with the FutureNeuro aim to “develop new technologies and solutions for the treatment, diagnosis, and monitoring of chronic and rare neurological diseases”. We anticipate further preclinical development of epitranscriptomic drugs by industry partners as a direct result of this proposal.
Wyszukiwanie danych OpenAIRE...
Podczas wyszukiwania danych OpenAIRE wystąpił błąd
Brak wyników